Shilpa Medicare's Transformative Innovation in FY2024-25: A Year of Advancements in APIs, Formulations, and Biosimilars
Shilpa Medicare has shown remarkable progress in FY2024-25 across its core business verticals of APIs, Formulations, and Biosimilars. The API division continues to innovate in complex molecules and advanced synthesis, with a focus on Oncology and GLP-1 technologies. The Formulations division has redefined patient care with several first-to-market innovations, and Shilpa's strategic expansion into Rest of World markets underscores its commitment to bringing high-quality, affordable pharmaceuticals to patients worldwide. The Biosimilars division is gaining momentum, with Adalimumab demonstrating strong market performance and the initiation of Phase III clinical trials for Aflibercept. Shilpa's CDMO business offers end-to-end solutions, with strategic partnerships highlighting its role as a trusted CDMO partner for innovative biopharma companies.
Key Highlights
- API division making significant strides in developing complex molecules, particularly in Oncology, and advancing GLP-1, Peptide, and Polymers technologies.
- Formulations division achieved significant milestones with first-to-market innovations and expanded into Rest of World markets.
- Biosimilars division gained momentum, with Adalimumab demonstrating strong market performance and Phase III trials initiated for Aflibercept.
- CDMO business offers end-to-end solutions, with strategic partnerships showcasing Shilpa's role as a trusted CDMO partner.
- Shilpa Medicare remains committed to driving sustainable growth through continuous R&D investment, technological advancement, and strategic partnerships.